Feb. 12, 2026 – CellProthera has acquired the transendocardial catheter originally developed by Celyad Oncology. This acquisition is a critical step for CellProthera as it prepares to enter the pivotal Phase 3 clinical trial. The transendocardial catheter is a key enabling technology of its therapeutic approach, delivering targeted application of proprietary processed CD34 + stem cells directly into damaged cardiac tissue. The transaction includes all intellectual property rights and associated technical documentation.
By securing full ownership of this catheter technology, CellProthera significantly strengthens its position in intramyocardial administration and achieves end-to-end integration of its value chain — from autologous stem cell manufacturing to precise cardiac delivery. Full control of this critical delivery platform positions CellProthera to optimize clinical execution, streamline development, and accelerate commercialization. Originally developed by Celyad Oncology, the catheter has demonstrated a strong safety and performance profile in more than 100 patients, ensuring accurate cell distribution while minimizing procedural risk.
“This acquisition allows CellProthera to fully own its key processes — from cell production to delivery at the damaged tissue,” said Matthieu de Kalbermatten, CEO of CellProthera. “The catheter developed by Celyad offers our patients exceptional safety and precision, ensuring targeted cell distribution in the affected areas of the heart. Novel catheter injection technology and imaging will play a central role in effective delivery during our upcoming pivotal Phase 3 trial.”
“We are pleased to see this technology continue its journey toward clinical and patient impact,” said Michel Lussier, Co-founder and Board Member of Celyad Oncology. “CellProthera is ideally positioned to take this innovation forward, building on the promising results of its Phase 2 program and its imminent Phase 3 trial.”
CellProthera’s proprietary therapy is designed to enhance regeneration of cardiac tissue and help improve function following severe myocardial infarction by delivering autologous stem cells directly into the affected myocardium. The integration of this proven delivery system further enhances the robustness and scalability of the Company’s clinical program. With this acquisition, CellProthera aims to consolidate its position as a leading innovator in regenerative cardiology and reinforces its long-term commitment to advancing transformative cardiovascular therapies.
CellProthera is headquartered in Mulhouse, France. For more information, visit www.cellprothera.com.
May 28, 2026 
